< 1 minute read
Dec. 10, 2021

Aficamten: Next-Generation Myosin Inhibitor


oral QD myosin inhibitor (IC50 = 1.4 µM) Ph. II candidate for cardiomyopathy (5-30 mg) from HTS w/ bovine cardiac muscle myofibrils Journal of Medicinal Chemistry Cytokinetics, South San Francisco, CA

Drug Hunter Team

The Cytokinetics next-generation myosin inhibitor, aficamten , is a phase II candidate for genetic hypertrophic cardiomyopathies, and is orally dosed between 5-30 mg QD. It follows BMS’s mavacamten ( acquired from Myokardia in a $13.1B deal), whose NDA is under review by the FDA. This class of molecules is intended to address hypertrophic [...]



Other molecules you may be interested in